Novo Nordisk A/S ADR
(NVO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 12,343,020 | 11,741,240 | 11,689,950 | 11,018,080 | 12,261,320 |
| Cost of Goods | 2,324,081 | 2,803,766 | 1,953,877 | 1,818,779 | 1,862,583 |
| Gross Profit | 10,018,940 | 8,937,476 | 9,736,073 | 9,199,297 | 10,398,740 |
| Operating Expenses | 4,961,204 | 5,229,641 | 4,649,357 | 3,726,666 | 5,154,582 |
| Operating Income | 5,057,817 | 3,708,601 | 5,087,593 | 5,473,410 | 5,244,737 |
| Interest Expense | -219,959 | -239,285 | 754,112 | 731,321 | 416,784 |
| Other Income | 122,920 | 48,076 | 808,260 | 483,267 | 243,872 |
| Pre-tax Income | 5,400,696 | 3,995,962 | 5,141,741 | 5,225,356 | 5,071,825 |
| Income Tax | 1,152,933 | 863,023 | 1,110,634 | 1,128,659 | 1,045,207 |
| Net Income Continuous | 4,247,765 | 3,132,940 | 4,031,106 | 4,096,697 | 4,026,618 |
| Net Income | $4,247,765 | $3,132,940 | $4,031,106 | $4,096,697 | $4,026,618 |
| EPS Basic Total Ops | 0.95 | 0.70 | 0.91 | 0.92 | 0.90 |
| EPS Basic Continuous Ops | 0.96 | 0.70 | 0.91 | 0.92 | 0.91 |
| EPS Diluted Total Ops | 0.95 | 0.70 | 0.91 | 0.92 | 0.90 |
| EPS Diluted Continuous Ops | 0.95 | 0.70 | 0.91 | 0.92 | 0.90 |
| EPS Diluted Before Non-Recurring Items | 1.00 | 1.02 | 0.97 | 0.92 | 0.91 |
| EBITDA(a) | $5,814,521 | $4,962,330 | $5,864,822 | $6,013,824 | $5,965,065 |